myxoid neurothekeomas would display neural differentiation; the cellular subtype, fibrohistiocytic differentiation. 5 Neuroectodermal antigens -such as NKI/C3, PGP9.5, and Leu-7 -and fibrohistiocytic antigens -including XIIIa factor, vimentin, EMA, or SMA -have limited diagnostic value in differentiating the subtypes. 4 S-100 negative myxoid neurothekeoma is rare, with a few cases reported in literature. 4 Some authors consider that the immunohistochemical profile is more important than histopathology to establish the subtype of the tumor. There are some similar cases reporting cellular myxoid neurothekeoma. 4 Some authors characterize this variant as a new entity, which features histopathology results typical of neurothekeomas, negative immunohistochemical markers for neural differentiation, and positive results for other markers (such as CD-68). 4 Neurothekeoma treatment consists of the complete excision of the tumors with low recurrence rates.
